Evolus launches Nuceiva or botulinum toxin type A, in Spain

Evolus has commercially launched Nuceiva, botulinum toxin type A, in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals. Nuceiva is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown or glabellar lines , when the severity of the above facial lines has an important psychological impact in adults below 65 years of age. “Launching our direct operations in Spain, one of Europe’s largest aesthetic markets, underscores our commitment to strategic geographic expansion,” said David Moatazedi, President and CEO of Evolus. “This milestone supports our goal of fueling market growth worldwide by establishing a strong presence in key regions. Our continued success in entering new markets positions us for sustained above-market growth in the aesthetic neurotoxin sector.” “Offering treatments that deliver pleasing and long-lasting results to my patients is a priority for me,” said Dr. Jaime Tufet, Medical Director at Clinica Tufet, one of Spain’s premier aesthetic clinics. “We are very pleased to be able to offer Nuceivato our patients.”